| Autor: |
Booth WT; Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. wbooth@jcsu.edu., Walker NB; Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. nbwalker@wakehealth.edu., Lowther WT; Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. tlowther@wakehealth.edu.; Center for Molecular Signaling, Wake Forest University, 1834 Wake Forest Road, Winston-Salem, NC 27109, USA. tlowther@wakehealth.edu., Howlett AC; Center for Molecular Signaling, Wake Forest University, 1834 Wake Forest Road, Winston-Salem, NC 27109, USA. ahowlett@wakehealth.edu.; Department of Physiology and Pharmacology, Center for Research on Substance Use and Addiction, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. ahowlett@wakehealth.edu. |
| Abstrakt: |
Cannabinoid receptor interacting protein 1a (CRIP1a) is an important CB 1 cannabinoid receptor-associated protein, first identified from a yeast two-hybrid screen to modulate CB 1 -mediated N-type Ca 2+ currents. In this paper we review studies of CRIP1a function and structure based upon in vitro experiments and computational chemistry, which elucidate the specific mechanisms for the interaction of CRIP1a with CB 1 receptors. N18TG2 neuronal cells overexpressing or silencing CRIP1a highlighted the ability of CRIP1 to regulate cyclic adenosine 3',5'monophosphate (cAMP) production and extracellular signal-regulated kinase (ERK1/2) phosphorylation. These studies indicated that CRIP1a attenuates the G protein signaling cascade through modulating which Gi/o subtypes interact with the CB 1 receptor. CRIP1a also attenuates CB 1 receptor internalization via β-arrestin, suggesting that CRIP1a competes for β-arrestin binding to the CB 1 receptor. Predictions of CRIP1a secondary structure suggest that residues 34-110 are minimally necessary for association with key amino acids within the distal C-terminus of the CB 1 receptor, as well as the mGlu 8a metabotropic glutamate receptor. These interactions are disrupted through phosphorylation of serines and threonines in these regions. Through investigations of the function and structure of CRIP1a, new pharmacotherapies based upon the CRIP-CB 1 receptor interaction can be designed to treat diseases such as epilepsy, motor dysfunctions and schizophrenia. |
